ID.1
Item
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
boolean
ID.2
Item
has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
boolean
ID.3
Item
has a screening serum testosterone level >150 ng/dl
boolean
ID.4
Item
has an eastern cooperative oncology group (ecog) score of ≤2
boolean
ID.5
Item
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
boolean
ID.6
Item
is currently treated with a 5-alpha reductase inhibitor
boolean
ID.7
Item
is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
boolean
ID.8
Item
is in need of neoadjuvant hormonal therapy
boolean
ID.9
Item
has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
boolean